Funding Opportunity PA-18-819 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages the translation of technologies for brain or behavioral research from academic and other non-small business research sectors to the marketplace. Encouraged from Small Business Concerns (SBCs) are Small Business Innovation Research (SBIR) grant applications that propose to further develop, make more robust, and make more user-friendly such technologies in preparation for commercial dissemination. It is expected that this activity will require partnerships and close collaboration between the original developers of these technologies and SBCs, which may be accomplished in any of a number of ways, including the use of multiple program directors/principal investigators.

Making a Notch in the Evolution of the Human Cortex.

Dev Cell. 2018 Jun 04;45(5):548-550

Authors: Bizzotto S, Walsh CA

Abstract
The unique structure and function of the human brain ultimately results from the action of evolution on the human genome. In a recent issue of Cell, Fiddes et al. (2018) and Suzuki et al. (2018) describe human-specific NOTCH2 paralogs that enhance neural progenitor proliferation and expand cortical neurogenesis.

PMID: 29870717 [PubMed - in process]

Related Articles

Establishment of New National Rare Disease (Nambyo) Registry and Registry Guidelines in Japan.

Stud Health Technol Inform. 2017;245:536-538

Authors: Mizushima H, Tanabe M, Sugamori Y, Sato Y, Ogata H

Abstract
A New legal structure for rare disease (nambyo) has been established in Japan this year, after 42 years of measures of nambyo. We have been accumulating registry for nambyo from 2003, however, as it was based on paper registration, quality was not enough. Our new registry system will be based under ISO13606 which is a new medical international standard. Authorized doctors can put in data On Line by the new system, which has data cleaning filter for accurate data entry. Patients will be supported their medical expense by authorization by this system, so the registry will be efficient.

PMID: 29295152 [PubMed - indexed for MEDLINE]

Das Myelosarkom der Hypophyse – eine Rarität eines isolierten Rezidivs einer akuten myeloischen Leukämie.

Rofo. 2018 Mar;190(3):273-274

Authors: Fleischmann T, Hilgendorf I, Franiel T

PMID: 29156477 [PubMed - indexed for MEDLINE]

44 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results:

"systems biology"

These pubmed results were generated on 2018/06/06

PubMed comprises more than millions of citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

Related Articles

A shared cis-regulatory module activates transcription in the suspensor of plant embryos.

Proc Natl Acad Sci U S A. 2018 Jun 04;:

Authors: Henry KF, Bui AQ, Kawashima T, Goldberg RB

Abstract
The mechanisms controlling the transcription of gene sets in specific regions of a plant embryo shortly after fertilization remain unknown. Previously, we showed that G564 mRNA, encoding a protein of unknown function, accumulates to high levels in the giant suspensor of both Scarlet Runner Bean (SRB) and Common Bean embryos, and a cis-regulatory module containing three unique DNA sequences, designated as the 10-bp, Region 2, and Fifth motifs, is required for G564 suspensor-specific transcription [Henry KF, et al. (2015) Plant Mol Biol 88:207-217; Kawashima T, et al. (2009) Proc Natl Acad Sci USA 106:3627-3632]. We tested the hypothesis that these motifs are also required for transcription of the SRB GA 20-oxidase gene, which encodes a gibberellic acid hormone biosynthesis enzyme and is coexpressed with G564 at a high level in giant bean suspensors. We used deletion and gain-of-function experiments in transgenic tobacco embryos to show that two GA 20-oxidase DNA regions are required for suspensor-specific transcription, one in the 5' UTR (+119 to +205) and another in the 5' upstream region (-341 to -316). Mutagenesis of sequences in these two regions determined that the cis-regulatory motifs required for G564 suspensor transcription are also required for GA 20-oxidase transcription within the suspensor, although the motif arrangement differs. Our results demonstrate the flexibility of motif positioning within a cis-regulatory module that activates gene transcription within giant bean suspensors and suggest that G564 and GA 20-oxidase comprise part of a suspensor gene regulatory network.

PMID: 29866850 [PubMed - as supplied by publisher]

Changes on the Horizon for Drug Repurposing, Rescue, and Repositioning at ASSAY.

Assay Drug Dev Technol. 2018 Jun 05;:

Authors: Melancon BJ, Mucke HAM

PMID: 29870272 [PubMed - as supplied by publisher]

Related Articles

Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds.

Front Chem. 2018;6:138

Authors: Huang H, Zhang G, Zhou Y, Lin C, Chen S, Lin Y, Mai S, Huang Z

Abstract
This article is a systematic review of reverse screening methods used to search for the protein targets of chemopreventive compounds or drugs. Typical chemopreventive compounds include components of traditional Chinese medicine, natural compounds and Food and Drug Administration (FDA)-approved drugs. Such compounds are somewhat selective but are predisposed to bind multiple protein targets distributed throughout diverse signaling pathways in human cells. In contrast to conventional virtual screening, which identifies the ligands of a targeted protein from a compound database, reverse screening is used to identify the potential targets or unintended targets of a given compound from a large number of receptors by examining their known ligands or crystal structures. This method, also known as in silico or computational target fishing, is highly valuable for discovering the target receptors of query molecules from terrestrial or marine natural products, exploring the molecular mechanisms of chemopreventive compounds, finding alternative indications of existing drugs by drug repositioning, and detecting adverse drug reactions and drug toxicity. Reverse screening can be divided into three major groups: shape screening, pharmacophore screening and reverse docking. Several large software packages, such as Schrödinger and Discovery Studio; typical software/network services such as ChemMapper, PharmMapper, idTarget, and INVDOCK; and practical databases of known target ligands and receptor crystal structures, such as ChEMBL, BindingDB, and the Protein Data Bank (PDB), are available for use in these computational methods. Different programs, online services and databases have different applications and constraints. Here, we conducted a systematic analysis and multilevel classification of the computational programs, online services and compound libraries available for shape screening, pharmacophore screening and reverse docking to enable non-specialist users to quickly learn and grasp the types of calculations used in protein target fishing. In addition, we review the main features of these methods, programs and databases and provide a variety of examples illustrating the application of one or a combination of reverse screening methods for accurate target prediction.

PMID: 29868550 [PubMed]

Related Articles

Drug Repositioning for Effective Prostate Cancer Treatment.

Front Physiol. 2018;9:500

Authors: Turanli B, Grøtli M, Boren J, Nielsen J, Uhlen M, Arga KY, Mardinoglu A

Abstract
Drug repositioning has gained attention from both academia and pharmaceutical companies as an auxiliary process to conventional drug discovery. Chemotherapeutic agents have notorious adverse effects that drastically reduce the life quality of cancer patients so drug repositioning is a promising strategy to identify non-cancer drugs which have anti-cancer activity as well as tolerable adverse effects for human health. There are various strategies for discovery and validation of repurposed drugs. In this review, 25 repurposed drug candidates are presented as result of different strategies, 15 of which are already under clinical investigation for treatment of prostate cancer (PCa). To date, zoledronic acid is the only repurposed, clinically used, and approved non-cancer drug for PCa. Anti-cancer activities of existing drugs presented in this review cover diverse and also known mechanisms such as inhibition of mTOR and VEGFR2 signaling, inhibition of PI3K/Akt signaling, COX and selective COX-2 inhibition, NF-κB inhibition, Wnt/β-Catenin pathway inhibition, DNMT1 inhibition, and GSK-3β inhibition. In addition to monotherapy option, combination therapy with current anti-cancer drugs may also increase drug efficacy and reduce adverse effects. Thus, drug repositioning may become a key approach for drug discovery in terms of time- and cost-efficiency comparing to conventional drug discovery and development process.

PMID: 29867548 [PubMed]

Related Articles

Trends of Clinical Trials for Drug Development in Rare Diseases.

Curr Clin Pharmacol. 2018 Jun 03;:

Authors: Sakate R, Fukagawa A, Takagaki Y, Okura H, Matsuyama A

Abstract
BACKGROUND: Drug development for rare diseases is challenging because very few patients suffer from such diseases, and thus it is difficult to obtain relevant data. In these difficult conditions, it must be informative to assess a trend of drug development so far, to plot a new strategy such as drug repositioning.
OBJECTIVE: In this study, data from clinical trials belonging to three international registries were first outlined and compared.
METHODS: ClinicalTrials.gov (NCT), EU Clinical Trials Register (EUCTR), and the Japan Primary Registries Network (JPRN) were analyzed. Clinical trials with information on rare diseases (Orphanet) and drugs (DrugBank) were extracted by text-mining.
RESULTS: A total of 28,526 clinical trials were considered, which studied 1,535 rare diseases and 1,539 drugs. NCT had the largest number of trials, involving 1,252 diseases and 1,332 drugs. However, EUCTR and JPRN also had a considerable number of registry-specific diseases (250 and 22, respectively) and drugs (172 and 29, respectively). After analyzing all trials, it was found that most diseases had been studied in only a limited number of trials; 70% of diseases had been studied in fewer than 10 trials, and 28% had been studied in only one. It was also found that most trials were for cancer-related rare diseases. The number of trials for non-cancer-related rare diseases were much fewer.
CONCLUSION: This study revealed details of the three registries and bias among rare diseases in the number of the trials. This information could contribute to drug-repositioning and a broad range of rare disease studies.

PMID: 29866013 [PubMed - as supplied by publisher]

Related Articles

Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals.

J Antimicrob Chemother. 2018 Jun 03;:

Authors: de Almeida TB, de Azevedo MCVM, Pinto JFDC, Ferry FRA, da Silva GAR, de Castro IJ, Baker P, Tanuri A, Haas DW, Cardoso CC

Abstract
Objectives: There are limited data regarding efavirenz pharmacogenetics in admixed populations. The Brazilian population is highly admixed. In a Brazilian cohort, we sought to characterize associations between efavirenz adverse effects (all-cause and CNS) and polymorphisms in seven genes known or suspected to affect efavirenz metabolism and transport.
Methods: We studied 225 HIV-positive individuals who had been prescribed efavirenz-containing regimens at a hospital in Rio de Janeiro, Brazil. Eighty-nine cases had efavirenz adverse effects, including 43 with CNS adverse effects, while 136 controls had no adverse effect of any antiretroviral after treatment for at least 6 months. A total of 67 candidate polymorphisms in ABCB1, CYP2A6, CYP2B6, CYP3A4, CYP3A5, NR1I2 and NR1I3 genes were selected for association analysis. Admixture was assessed using 28 ancestry-informative polymorphisms previously validated for the Brazilian population. Associations were evaluated with logistic regression models adjusted for sex and genetic ancestry.
Results: There was extensive African, European and Native American admixture in the cohort. Increased all-cause adverse effects were associated with the CYP2B6 genotype combination 15582CC-516TT-983TT (OR = 7.26, P = 0.003) and with the CYP2B6 slow metabolizer group 516TT or 516GT-983CT (OR = 3.10, P = 0.04). CNS adverse effects were nominally associated with CYP3A4 rs4646437 (OR = 4.63, P = 0.014), but not after adjusting for multiple comparisons.
Conclusions: In a highly admixed Brazilian cohort, the CYP2B6 slow metabolizer genotype was associated with an increased risk of efavirenz adverse effects.

PMID: 29868865 [PubMed - as supplied by publisher]

Related Articles

Betulinic Acid Exerts Cytotoxic Activity Against Multidrug-Resistant Tumor Cells via Targeting Autocrine Motility Factor Receptor (AMFR).

Front Pharmacol. 2018;9:481

Authors: Saeed MEM, Mahmoud N, Sugimoto Y, Efferth T, Abdel-Aziz H

Abstract
Betulinic acid (BetA) is a naturally occurring pentacyclic triterpene isolated from the outer bark of white-barked birch trees and many other medicinal plants. Here, we studied betulinic acid's cytotoxic activity against drug-resistant tumor cell lines. P-glycoprotein (MDR1/ABCB1) and BCRP (ABCG2) are known ATP-binding cassette (ABC) drug transporters that mediating MDR. ABCB5 is a close relative to ABCB1, which also mediates MDR. Constitutive activation of the EGF receptor is tightly linked to the development of chemotherapeutic resistance. BetA inhibited P-gp, BCRP, ABCB5 and mutation activated EGFR overexpressing cells with similar efficacy as their drug-sensitive parental counterparts. Furthermore, the mRNA expressions of ABCB1, BCRP, ABCB5 and EGFR were not related to the 50% inhibition concentrations (IC50) for BetA in a panel of 60 cell lines of the National Cancer Institute (NCI), USA. In addition to well-established MDR mechanisms, we attempted to identify other molecular mechanisms that play a role in mediating BetA's cytotoxic activity. For this reason, we performed COMPARE and hierarchical cluster analyses of the transcriptome-wide microarray-based mRNA expression of the NCI cell lines panel. Various genes significantly correlating to BetA's activity were involved in different biological processes, e.g., cell cycle regulation, microtubule formation, signal transduction, transcriptional regulation, chromatin remodeling, cell adhesion, tumor suppression, ubiquitination and proteasome degradation. Immunoblotting and in silico analyses revealed that the inhibition of AMFR activity might be one of the mechanisms for BetA to overcome MDR phenotypes. In conclusion, BetA may have therapeutic potential for the treatment of refractory tumors.

PMID: 29867487 [PubMed]

Related Articles

Pharmacogenetic Aspects of the Interaction of AT1 Receptor Antagonists With ATP-Binding Cassette Transporter ABCG2.

Front Pharmacol. 2018;9:463

Authors: Ripperger A, Krischer A, Robaa D, Sippl W, Benndorf RA

Abstract
The ATP-binding cassette transporter ABCG2 (BCRP and MXR) is involved in the absorption, distribution, and elimination of numerous drugs. Thus, drugs that are able to reduce the activity of ABCG2, e.g., antihypertensive AT1 receptor antagonists (ARBs), may cause drug-drug interactions and compromise drug safety and efficacy. In addition, genetic variability within the ABCG2 gene may influence the ability of the transporter to interact with ARBs. Thus, the aim of this study was to characterize the ARB-ABCG2 interaction in the light of naturally occurring variations (F489L, R482G) or amino acid substitutions with in silico-predicted relevance for the ARB-ABCG2 interaction (Y469A; M483F; Y570A). For this purpose, ABCG2 variants were expressed in HEK293 cells and the impact of ARBs on ABCG2 activity was studied in vitro using the pheophorbide A (PhA) efflux assay. First, we demonstrated that both the F489L and the Y469A substitution, respectively, reduced ABCG2 protein levels in these cells. Moreover, both substitutions enhanced the inhibitory effect of candesartan cilexetil, irbesartan, losartan, and telmisartan on ABCG2-mediated PhA efflux, whereas the R482G substitution blunted the inhibitory effect of candesartan cilexetil and telmisartan in this regard. In contrast, the ARB-ABCG2 interaction was not altered in cells expressing either the M483F or the Y570A variant, respectively. In conclusion, our data indicate that the third transmembrane helix and adjacent regions of ABCG2 may be of major importance for the interaction of ARBs with the ABC transporter. Moreover, we conclude from our data that individuals carrying the F489L polymorphism may be at increased risk of developing ABCG2-related drug-drug interactions in multi-drug regimens involving ARBs.

PMID: 29867471 [PubMed]

Related Articles

An automated computed tomography score for the cystic fibrosis lung.

Eur Radiol. 2018 Jun 04;:

Authors: Chassagnon G, Martin C, Burgel PR, Hubert D, Fajac I, Paragios N, Zacharaki EI, Legmann P, Coste J, Revel MP

Abstract
OBJECTIVES: To develop an automated density-based computed tomography (CT) score evaluating high-attenuating lung structural abnormalities in patients with cystic fibrosis (CF).
METHODS: Seventy adult CF patients were evaluated. The development cohort comprised 17 patients treated with ivacaftor, with 45 pre-therapeutic and follow-up chest CT scans. Another cohort of 53 patients not treated with ivacaftor was used for validation. CT-density scores were calculated using fixed and adapted thresholds based on histogram characteristics, such as the mode and standard deviation. Visual CF-CT score was also calculated. Correlations between the CT scores and forced expiratory volume in 1 s (FEV1% pred), and between their changes over time were assessed.
RESULTS: On cross-sectional evaluation, the correlation coefficients between FEV1%pred and the automated scores were slightly lower to that of the visual score in the development and validation cohorts (R = up to -0.68 and -0.61, versus R = -0.72 and R = -0.64, respectively). Conversely, the correlation to FEV1%pred tended to be higher for automated scores (R = up to -0.61) than for visual score (R = -0.49) on longitudinal follow-up. Automated scores based on Mode + 3 SD and Mode +300 HU showed the highest cross-sectional (R = -0.59 to -0.68) and longitudinal (R = -0.51 to -0.61) correlation coefficients to FEV1%pred.
CONCLUSIONS: The developed CT-density score reliably quantifies high-attenuating lung structural abnormalities in CF.
KEY POINTS: • Automated CT score shows moderate to good cross-sectional correlations with FEV 1 %pred . • CT score has potential to be integrated into the standard reporting workflow.

PMID: 29869171 [PubMed - as supplied by publisher]

Related Articles

The liver-first approach for combined lung and liver transplantation.

Eur J Cardiothorac Surg. 2018 Jun 03;:

Authors: Salman J, Grannas G, Ius F, Sommer W, Siemeni T, Avsar M, Kuehn C, Boethig D, Fleissner F, Bobylev D, Gottlieb J, Klempnauer J, Welte T, Haverich A, Tudorache I, Warnecke G, Lehner F

Abstract
OBJECTIVES: Combined lung and liver transplantation (Lu-LTx) is an established therapy for patients with cystic fibrosis. The initial sequence has primarily been lung first. We changed the sequence to 'liver first' in 2006. The aim of this study is to present outcomes of this procedure.
METHODS: The records of combined lung and liver transplant patients treated at our institution between April 1999 and November 2016 were reviewed retrospectively.
RESULTS: A total of 27 patients received a combined Lu-LTx at our institute. Seventeen patients underwent Lu-LTx beginning with the lung transplantation. In this group, 5 patients had cystic fibrosis (lung first). The other 10 patients received the liver transplant first (liver first). All patients in this group had cystic fibrosis as underlying disease. The lung-first group showed a trend towards longer stays in the intensive care unit (ICU) and in the hospital [median 17 days in the ICU, interquartile range (IQR) 3-47 and 55 in-hospital days, IQR 29-108] than the liver-first group (median 6 days in the ICU, IQR 4-19 and 33 in-hospital days, IQR 26-63). The 90-day, 1- and 5-year survival rates were 80%, 60% and 20% in the lung-first group vs 90%, 79% and 79% in the liver-first group.
CONCLUSIONS: We present the largest series of patients following combined Lu-LTx according to the liver-first approach. The liver-first sequence results in favourable outcomes in our cohort of combined lung and liver transplants.

PMID: 29868836 [PubMed - as supplied by publisher]

Related Articles

INCREASING BURDEN OF ANTIMICROBIAL RESISTANCE IN PSEUDOMONAS AERUGINOSA FROM ADULT PATIENTS WITH CYSTIC FIBROSIS (CF) IN NORTHERN IRELAND: THEN AND NOW.

Ulster Med J. 2018 May;87(2):129-130

Authors: Gramegna A, Moore JE, McCaughan J, Millar BC, Ewing J, Elborn JS, Blasi F, Downey DG

PMID: 29867273 [PubMed - in process]

Related Articles

In vitro and intracellular activity of imipenem combined to rifabutin and avibactam against Mycobacterium abscessus.

Antimicrob Agents Chemother. 2018 Jun 04;:

Authors: Le Run E, Arthur M, Mainardi JL

Abstract
Repurposing drugs may be useful as an add-on in the treatment of Mycobacterium abscessus pulmonary infections, which are particularly difficult to cure. M. abscessus naturally produces a β-lactamase, BlaMab, which is inhibited by avibactam. The recommended regimens include imipenem, which is hydrolyzed by BlaMab and used without any β-lactamase inhibitor. Here, we determine whether the addition of rifabutin improves the activity of imipenem alone or in combination with avibactam against M. abscessus CIP104536. Rifabutin at 16 μg/ml was only bacteriostatic (MIC = 4 μg/ml) and was moderately synergistic in combination with imipenem (FIC index of 0.38). Addition of rifabutin (16 μg/ml) moderately increased killing by a low (8 μg/ml) but not by a high (32 μg/ml) concentration of imipenem. Addition of avibactam (4 μg/ml) did not further increase killing by the former combination. In infected macrophages, rifabutin (16 μg/ml) increased the activity of imipenem at 8 and 32 μg/ml achieving 3- and 100-fold reductions in the number of intracellular bacteria, respectively. Avibactam (16 μg/ml) improved killing by imipenem at 8 μg/ml. A 5-fold killing was obtained for a triple combination comprising avibactam (16 μg/ml) and therapeutically-achievable doses of imipenem (8 μg/ml) and rifabutin (1 μg/ml). These results indicate that the imipenem-rifabutin combination should be further considered for the treatment of M. abscessus pulmonary infections in cystic fibrosis patients and that addition of a β-lactamase inhibitor might improve its efficacy. Mechanistically, the impact of BlaMab inhibition by avibactam on antibiotic activity was assessed by comparing CIP104536 and a β-lactamase-deficient derivative.

PMID: 29866869 [PubMed - as supplied by publisher]

Related Articles

RsmV a small non-coding regulatory RNA in Pseudomonas aeruginosa that sequesters RsmA and RsmF from target mRNAs.

J Bacteriol. 2018 Jun 04;:

Authors: Janssen KH, Diaz MR, Gode CJ, Wolfgang MC, Yahr TL

Abstract
The Gram-negative opportunistic pathogen Pseudomonas aeruginosa has distinct genetic programs that favor either acute or chronic virulence gene expression. Acute virulence is associated with twitching and swimming motility, expression of a type III secretion system (T3SS), and the absence of alginate, Psl, or Pel polysaccharide production. Traits associated with chronic infection include growth as a biofilm, reduced motility, and expression of a type VI secretion system (T6SS). The Rsm post-transcriptional regulatory system plays important roles in the inverse control of phenotypes associated with acute and chronic virulence. RsmA and RsmF are RNA-binding proteins that interact with target mRNAs to control gene expression at the post-transcriptional level. Previous work found that RsmA activity is controlled by at least three small, non-coding regulatory RNAs (RsmW, RsmY, and RsmZ). In this study, we took an in-silico approach to identify additional sRNAs that might function in the sequestration of RsmA and/or RsmF and identified RsmV, a 192 nt transcript with four predicted RsmA/RsmF consensus binding sites. RsmV is capable of sequestering RsmA and RsmF in vivo to activate translation of tssA1, a component of the T6SS, and to inhibit T3SS gene expression. Each of the predicted RsmA/RsmF consensus binding sites contribute to RsmV activity. Electrophoretic mobility shifts assays show that RsmF binds RsmV with >10-fold higher affinity than RsmY and RsmZ. Gene expression studies revealed that the temporal expression pattern of RsmV differs from RsmW, RsmY, and RsmZ. These findings suggest that each sRNA may play distinct roles in controlling RsmA and RsmF activity.IMPORTANCE The CsrA/RsmA family of RNA-binding proteins play important roles in post-transcriptional control of gene expression. The activity of CsrA/RsmA proteins is controlled by small non-coding RNAs that function as decoys to sequester CsrA/RsmA from target mRNAs. Pseudomonas aeruginosa has two CsrA family proteins (RsmA and RsmF) and at least four sequestering sRNAs (RsmV [identified in this study], RsmW, RsmY, RsmZ) that control RsmA/RsmF activity. RsmY and RsmZ are the primary sRNAs that sequester RsmA/RsmF, and RsmV and RsmW appear to play smaller roles. Differences in the temporal expression and absolute levels of the sRNAs and in their binding affinities for RsmA/RsmF may provide a mechanism of fine-tuning the output of the Rsm system in response to environmental cues.

PMID: 29866805 [PubMed - as supplied by publisher]

Related Articles

Predictors and variation of routine home discharge in critically ill adults with cystic fibrosis.

Heart Lung. 2018 Jun 01;:

Authors: Oud L, Chan YM

Abstract
BACKGROUND: The short-term outcomes of patients with cystic fibrosis (CF) surviving critical illness were not examined systematically.
OBJECTIVES: To determine the factors associated with and variation in rates of routine home discharge among ICU-managed adult CF patients.
METHODS: Predictors of routine home discharge and its hospital-level variation were examined in ICU-managed adults with cystic fibrosis in Texas during 2004-2013.
RESULTS: Older age, rural residence, and severity of illness decreased odds of routine home discharge, while hospitalization in facilities accredited as part of the Cystic Fibrosis Foundation Care Center Network nearly doubled the odds of routine home discharge. The median (interquartile) adjusted rate of routine home discharge was 62.0% (31.5-82.5).
CONCLUSIONS: The identified determinants of routine home discharge can inform clinical decision-making, while the demonstrated wide variation in adjusted across-hospital rates of routine home discharge of ICU-managed adults with CF can provide benchmark data for future quality improvement efforts.

PMID: 29866586 [PubMed - as supplied by publisher]

Related Articles

Cystic fibrosis: Beyond the airways. Report on the meeting of the basic science working group in Loutraki, Greece.

J Cyst Fibros. 2018 Jun 01;:

Authors: Amaral MD, Boj SF, Shaw J, Leipziger J, Beekman JM

Abstract
The European Cystic Fibrosis Society (ECFS) Basic Science Working Group (BSWG) organized a session on the topic "Cystic Fibrosis: Beyond the Airways", within the 15th ECFS Basic Science Conference which gathered around 200 researchers working in the basic science of CF. The session was organized and chaired by Margarida Amaral (BioISI, University of Lisboa, Portugal) and Jeffrey Beekman (University Medical Centre Utrecht, Netherlands) as Chair and Vice-Chair of the BSWG and its purpose was to bring attention of participants of the ECFS Basic Science Conference to "more forgotten" organs in CF disease. In this report we attempt to review and integrate the ideas that emerged at the session.

PMID: 29866530 [PubMed - as supplied by publisher]